IDXGInterpace Diagnostics GroupIDXG info
$1.56info-1.27%24h
Global rank33817
Market cap$6.74M
Change 7d-
YTD Performance47.17%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Interpace Diagnostics Group (IDXG) Stock Overview

    Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

    IDXG Stock Information

    Symbol
    IDXG
    Address
    Morris Corporate Center 1Parsippany, NJ 07054United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.interpace.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    855 776 6419

    Interpace Diagnostics Group (IDXG) Price Chart

    -
    Value:-

    Interpace Diagnostics Group Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.56
    N/A
    Market Cap
    $6.74M
    N/A
    Shares Outstanding
    4.32M
    N/A
    Employees
    94.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org